Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.75 |
| ▸ | MEN1 | O00255 | 3/20 | 0.66 |
| ▸ | MAOB | P27338 | 10/20 | 0.66 |
| ▸ | MAOA | P21397 | 3/20 | 0.60 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | CASP3 | P42574 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.58 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.58 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5139133 | 0.87 | HPGD (0.68) | KMT2ASMN1; SMN2MEN1NR1H4NPC1 | |
| SCHEMBL5974513 | 0.87 | MAOB (0.68) | KMT2ASMN1; SMN2MEN1MAOBMAOA | |
| SCHEMBL1436064 | 0.86 | KMT2A (0.76) | KMT2ASMN1; SMN2MEN1MAOBMAOA | |
| SCHEMBL29505938 | 0.85 | KMT2A (0.75) | KMT2ASMN1; SMN2MEN1NR1H4NPC1 | |
| SCHEMBL9373361 | 0.85 | MAOB (0.66) | KMT2ASMN1; SMN2MEN1MAOBMAOA | |
| SCHEMBL1333545 | 0.85 | KMT2A (0.75) | KMT2ASMN1; SMN2MEN1NR1H4NPC1 | |
| SCHEMBL29505934 | 0.85 | KMT2A (0.75) | KMT2ASMN1; SMN2MEN1NR1H4NPC1 | |
| SCHEMBL16953911 | 0.85 | KMT2A (0.56) | KMT2ASMN1; SMN2MEN1NR1H4NPC1 | |
| SCHEMBL1436145 | 0.84 | THRB (0.65) | KMT2ASMN1; SMN2MEN1MAOBMAOA | |
| SCHEMBL8403547 | 0.84 | MAOB (0.64) | KMT2ASMN1; SMN2MEN1MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4667458-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING SOS1 INHIBITOR AND ANTICANCER DRUG | Kanaph Therapeutics Inc. (KR) | 2025-12-24 | — | — | EP | disclosed |
| US-20240400518-A1 | SOS1 INHIBITOR AND USE THEREOF | CYRUS THERAPEUTICS INC. (KR) | 2024-12-05 | — | — | US | disclosed |
| US-20240376091-A1 | THIADIAZOLEAMIDE DERIVATIVES AND THEIR APPLICATIONS | ZHEJIANG UNIVERSITY (CN) | 2024-11-14 | — | — | US | disclosed |
| EP-4442318-A2 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC (US) | 2024-10-09 | — | — | EP | disclosed |
| WO-2024172631-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING SOS1 INHIBITOR AND ANTICANCER DRUG | 주식회사 카나프테라퓨틱스 | 2024-08-22 | — | — | WO | disclosed |
| EP-4389738-A1 | SOS1 INHIBITOR AND USE THEREOF | Kanaph Therapeutics Inc. (KR) | 2024-06-26 | — | — | EP | disclosed |
| CN-118119600-A | SOS1 inhibitors and uses thereof | 治纳辅医药科技有限公司 | 2024-05-31 | — | — | CN | disclosed |
| WO-2023219456-A1 | QUINOLINE-BASED HISTONE DEACETYLASE INHIBITORY SUBSTANCES, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME AS ACTIVE INGREDIENT | 숙명여자대학교 산학협력단 | 2023-11-16 | — | — | WO | disclosed |
| WO-2023022497-A1 | SOS1 INHIBITOR AND USE THEREOF | 주식회사 카나프테라퓨틱스 | 2023-02-23 | — | — | WO | disclosed |
| WO-2023022497-A1 | SOS1 INHIBITOR AND USE THEREOF | 주식회사 카나프테라퓨틱스 | 2023-02-23 | — | — | WO | disclosed |
| US-4479965-A | ANTILIPEMIC, ANTICHOLESTEROL AGENTS | SANKYO COMPANY, LIMITED (JP) | 1984-10-30 | — | — | US | disclosed |
| US-4451481-A | ANTICHOLESTEROL AGENTS | SANKYO COMPANY LIMITED (JP) | 1984-05-29 | — | — | US | disclosed |
| US-4447626-A | TREATMENT OF HYPERCHOLESTEROLEMIA | SANKYO COMPANY LIMITED (JP) | 1984-05-08 | — | — | US | disclosed |
| US-4438277-A | Hydronaphthalene derivatives | SANKYO COMPANY, LIMITED (JP) | 1984-03-20 | — | — | US | disclosed |
| EP-0076601-A1 | Octahydronaphthalene derivatives and their preparation | SANKYO COMPANY LIMITED (JP) | 1983-04-13 | — | — | EP | disclosed |
| EP-0074222-A1 | MB-530B derivatives, their preparation and pharmaceutical compositions containing them | SANKYO COMPANY LIMITED (JP) | 1983-03-16 | — | — | EP | disclosed |
| EP-0070649-A2 | ML-236B Derivatives, a process for their preparation and pharmaceutical compositions containing them | SANKYO COMPANY LIMITED (JP) | 1983-01-26 | — | — | EP | disclosed |
| EP-0065835-A1 | M-4 and iso M-4 derivatives, their preparation and compositions containing them | SANKYO COMPANY LIMITED (JP) | 1982-12-01 | — | — | EP | disclosed |
| EP-0065843-A1 | New M-4 and iso M-4 derivatives, their preparation and compositions containing them | SANKYO COMPANY LIMITED (JP) | 1982-12-01 | — | — | EP | disclosed |
| US-4361515-A | Antihyperlipemic dihydro-ML-236B derivatives, their preparation and use | SANKYO COMPANY, LIMITED (JP) | 1982-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240376091-A1 | THIADIAZOLEAMIDE DERIVATIVES AND THEIR APPLICATIONS | AR, GPER1, CYP19A1 | KMT2A 1661/4885SMN1; SMN2 4728/4885MEN1 4209/4885 |
| US-20240400518-A1 | SOS1 INHIBITOR AND USE THEREOF | SOS1, RAC1, SOS2 | KMT2A 4305/4885SMN1; SMN2 785/4885MEN1 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.